Investor relations

With the marketing approval for Sedaconda (isoflurane) in 15 EU countries and a great interest in inhaled sedation and our products, Sedana Medical is well-positioned for the future.

We are well on the way to the vision of making inhaled sedation a standard therapy in critical care.

Johan Spetz

CFO and Head of Investor Relations

ir@sedanamedical.com Send Email

The Share

See More

Press Releases

Sedana Medical AB’s Year-end report 2023

Regulatory

Full year sales at upper end of financial guidance and an exciting year ahead

Invitation to presentation of Sedana Medical’s fourth quarter and year-end report for 2023

Non-regulatory

Sedana Medical AB (publ) plans to present its fourth quarter and year-end report for 2023 on Thursda…

Sedana Medical files submission for paediatric indication

Non-regulatory

Sedana Medical AB (publ) announces that the company has submitted a Type II variation with the aim o…

View All Press Releases

Financial Calendar

Year-End Report 2023 15 February 2024 07:00
Annual Report 2023 15 April 2024 16:00

See More